Clinical trials
Metastatic Renal Cancer clinical trials
Below are recruiting metastatic renal cancer clinical trials, each written for real people, not researchers. We’re tracking 560 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06321081RecruitingPhase 2
Rechallenge combo for metastatic colorectal cancer
This trial tests a combination of three drugs (cetuximab, irinotecan, and envafolimab) as a ‘rechallenge’ – meaning if you had good results with cetuximab or irinotecan before, trying them again with a new drug might help shrink or control your cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05257993RecruitingPhase 1/Phase 2
Pancreatic cancer trial testing JPI-547 with standard chemo
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
Gyeonggi-doAges 19–79 - NCT05127824RecruitingPhase 2
Kidney cancer vaccine made from your own immune cells
This Phase 2 study tests a personalized kidney cancer vaccine made from your own immune cells. It aims to help your immune system recognize and attack clear cell kidney cancer after surgery, potentially lowering the chance of the cancer coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07156045RecruitingEarly Phase 1
Study of donor NK cells targeting PSMA for advanced prostate cancer
This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07136181RecruitingPhase 1/Phase 2
Study of NBM-BMX for advanced uveal melanoma that has spread
This trial tests a new oral drug, NBM-BMX, for people with metastatic uveal melanoma (melanoma of the eye that has spread). It aims to see if the drug is safe and effective. You may join if you have already tried some treatments, including tebentafusp if you are HLA-A*02:01 positive.
Scottsdale, ArizonaAges 18 years+ - NCT06059118RecruitingPhase 2
High-dose testosterone and a drug for advanced prostate cancer
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Baltimore, MarylandAges 18 years+ - NCT07853209RecruitingPhase 3
A study of a radioactive drug for men with metastatic prostate cancer
This study tests a new radioactive drug (called [177Lu]Ludotadipep) that targets a molecule on prostate cancer cells. It may help slow cancer growth in men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy.
Gyeonggi-doAges 19 years+ - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT07363486RecruitingPhase 1/Phase 2
Study of 225Ac-LNC1011 for advanced prostate cancer
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
Fuzhou, FujianAges 18–90 - NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Duarte, CaliforniaAges 18 years+ - NCT06367088RecruitingPhase 2
Combination drug therapy for advanced triple-negative breast cancer
This trial tests a new drug (cadonilimab) plus chemotherapy for people with advanced triple-negative breast cancer that has come back or spread. It aims to see if the combination works better than standard treatment.
Wuhan, HubeiAges 18–70 - NCT06189209RecruitingPhase 2
Tenalisib for metastatic triple-negative breast cancer
This trial tests a drug called Tenalisib in people with metastatic triple-negative breast cancer who have already tried 1 to 3 chemotherapy treatments. It aims to see if Tenalisib can help shrink tumors and improve outcomes.
Vijayawada, Andhra PradeshAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+ - NCT07615348RecruitingPhase 2
CD70 imaging to guide treatment breaks in advanced kidney cancer
This trial tests whether a special type of imaging scan (CD70-targeted PET/CT) can help doctors safely pause treatment in patients with advanced kidney cancer who respond well to standard immunotherapy and targeted therapy. The goal is to reduce unnecessary treatment while keeping the cancer controlled.
Nanjing, JiangsuAges 18 years+ - NCT07492628RecruitingPhase 1
Dual-target cell therapy for advanced bladder cancer
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
Shenzhen, GuangdongAges 18–75 - NCT07464366RecruitingPhase 2
MRG003 with or without putrelimab for salivary gland cancer
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07383857Recruiting
PULSAR radiation plus immunotherapy for advanced abdominal or pelvic tumors
This trial tests a special type of radiation called PULSAR combined with an immunotherapy drug (anti-PD-1) in people whose cancer has spread within the abdomen or pelvis. The goal is to see if this combination can shrink tumors and help people live longer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07235319RecruitingPhase 3
Immediate vs delayed radiation after chemo-immunotherapy for metastatic NPC
This trial tests whether giving radiation therapy to the main tumor right after chemo-immunotherapy is better than waiting until the cancer comes back, in people with newly diagnosed metastatic nasopharyngeal cancer. It aims to see which approach helps you live longer and have fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT04953897RecruitingPhase 1
Oral decitabine for cancer patients with kidney problems
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
Houston, TexasAges 18 years+ - NCT04747054RecruitingPhase 3
Radiation plus pembrolizumab for newly diagnosed metastatic head and neck cancer
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
AvignonAges 18 years+ - NCT07848828RecruitingPhase 4
Blood pressure and kidney study for prostate cancer treatment
This study looks at how a common prostate cancer treatment called androgen deprivation therapy (ADT) affects blood pressure and kidney function. It may help doctors understand and manage these side effects better.
Richmond, VirginiaAges 40 years+ - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Metastatic Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic renal cancer?
- Yes. Clin2 currently lists 560 recruiting metastatic renal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic renal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic renal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.